Juan-Luis Steegmann
Overview
Explore the profile of Juan-Luis Steegmann including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
8
Citations
857
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mosquera-Orgueira A, Perez-Encinas M, Hernandez-Sanchez A, Gonzalez-Martinez T, Arellano-Rodrigo E, Martinez-Elicegui J, et al.
Hemasphere
. 2022 Dec;
7(1):e818.
PMID: 36570691
Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful candidate selection. Therefore,...
2.
Hernandez-Boluda J, Pastor-Galan I, Arellano-Rodrigo E, Raya J, Perez-Encinas M, Ayala R, et al.
Br J Haematol
. 2022 Sep;
199(4):529-538.
PMID: 36089912
Available data have proved insufficient to develop consensus recommendations on the prevention of thrombosis and bleeding in myelofibrosis (MF). We evaluated the incidence and risk factors of vascular complications in...
3.
Cervantes F, Correa J, Perez I, Garcia-Gutierrez V, Redondo S, Colomer D, et al.
Ann Hematol
. 2016 Oct;
96(1):81-85.
PMID: 27717993
To determine whether a lower imatinib dose could minimize toxicity while maintaining the molecular response (MR), imatinib dose was reduced to 300 mg daily in 43 patients with chronic myeloid...
4.
Casado L, Garcia-Gutierrez J, Massague I, Giraldo P, Perez-Encinas M, de Paz R, et al.
Cancer Med
. 2015 Mar;
4(7):995-1002.
PMID: 25756742
Chronic myeloid leukemia patients display heterogeneous responses to imatinib. Survival depends on baseline clinical characteristics (including prognostic scoring systems) and on early response (such as >10% BCR-ABL/ABL ratio at 3 ...
5.
Baccarani M, Deininger M, Rosti G, Hochhaus A, Soverini S, Apperley J, et al.
Blood
. 2013 Jun;
122(6):872-84.
PMID: 23803709
Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase inhibitors, mandate regular updating of concepts and management. A European LeukemiaNet expert panel reviewed prior and new studies to update...
6.
Guilhot J, Baccarani M, Clark R, Cervantes F, Guilhot F, Hochhaus A, et al.
Blood
. 2012 Apr;
119(25):5963-71.
PMID: 22508936
The treatment policy of chronic myeloid leukemia (CML), particularly with tyrosine kinase inhibitors, has been influenced by several recent studies that were well designed and rapidly performed, but their interpretation...
7.
Giles F, Rosti G, Beris P, Clark R, le Coutre P, Mahon F, et al.
Expert Rev Hematol
. 2010 Nov;
3(6):665-73.
PMID: 21091142
Nilotinib (Tasigna(®)) is a more potent BCR-ABL inhibitor than imatinib and was designed to overcome imatinib's deficiencies. Nilotinib has significant efficacy in patients with chronic myeloid leukemia (CML) in chronic...
8.
Cervantes F, Hernandez-Boluda J, Steegmann J, Conde E, Alvarez-Larran A, Lopez-Jimenez J, et al.
Haematologica
. 2003 Oct;
88(10):1117-22.
PMID: 14555307
Background And Objectives: Imatinib mesylate has recently been shown to be highly effective in chronic-phase chronic myeloid leukemia (CML). The results of imatinib treatment in chronic-phase CML patients resistant or...